OncLive TV

Narjust Florez (Duma), MD, discusses nihilism in small cell lung cancer.

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Paolo Tarantino, MD, researcher, the European Institute of Oncology; clinical research fellow, Dana-Farber Cancer Institute, discusses the options available in the second line for patients with HER2-positive metastatic breast cancer.

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

Christine Ryan, MD, discusses the objectives for investigating different sequencing options for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.

Aiwu Ruth He, MD, PhD, discusses next steps for durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the efficacy of mFOLFIRINOX, a chemotherapy regimen consisting of oxaliplatin, irinotecan, leucovorin, and fluorouracil, prior to pancreatectomy in patients with borderline resectable pancreatic cancer.

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.

Alexey V. Danilov, MD, PhD, discusses the future of BTK inhibitors in chronic lymphocytic leukemia.

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

Erika P. Hamilton, MD, discusses testing used to identify patients with HER2-positive and HER2-low breast cancer.

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.

Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

David S. Hong, MD, discusses the significance of larotrectinib in the treatment of non–small cell lung cancer and other solid tumors harboring NTRK gene fusions.

Wade T. Iams, MD, discusses the evaluation of sotorasib in KRAS G12C–mutant solid tumors, including non–small cell lung cancer.

Hervé Tilly, MD, PhD, discusses the efficacy of polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone in an Asia subpopulation of patients with diffuse large B-cell lymphoma.

Shannon L. Maude, MD, PhD, discusses notable long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Xavier Leleu, MD, PhD, discusses how the declining prognosis of patients with multiple myeloma correlates with line of therapy and time after diagnosis, highlighting an unmet need for more effective later-line therapies in this population.

Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.

Neal Edward Ready, MD, PhD, discusses factors to consider when deciding when the use the regimen of nivolumab and ipilimumab plus chemotherapy in metastatic non–small cell lung cancer.